Pertuzumab, With Side Effect of Neutropenia, Approved in Europe for HER2 Breast Cancer

The European Medicines Agency has approved pertuzumab (Perjeta, Roche/Genentech) for patients with HER2-positive metastatic breast cancer, the company announced today. Pertuzumab is approved in combination with trastuzumab (Herceptin, Roche/Genentech) and docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The most common (>30%) adverse reactions observed with pertuzumab in combination with trastuzumab plus docetaxel were neutropenia, nausea, fatigue, rash, and peripheral neuropathy. The most common (>2%) grade 3/4 adverse reactions were neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, and fatigue.

Read more at Medscape

.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s